GRDN
BEARISH
$37.93
Live
Guardian Pharmacy Services, Inc. · NYSE
Target $40.83
(+7.7%)
$19.17
52W Range
$41.36
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 28, 2026
Market cap
$2.44B
P/E
48.63
ROE
26.6%
Profit margin
3.4%
Debt/Equity
0.21
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
GRDN presents a stark divergence between fundamental value and market price, with a Piotroski F-Score of 4/9 indicating only stable financial health. The stock is trading at a massive premium, with a current price of $37.93 compared to a Graham Number of $7.55 and an Intrinsic Value of $5.46. While growth metrics and analyst recommendations are strongly bullish, they are heavily offset by aggressive insider selling totaling over $419 million. The combination of extreme overvaluation and bearish insider sentiment outweighs the current growth trajectory.
Key Strengths
Strong ROE (26.61%) and ROA (13.68%) indicating efficient asset utilization
Low Debt/Equity ratio (0.21) suggesting a conservative leverage profile
Robust Q/Q earnings growth of 75.20% and YoY EPS growth of 54.2%
Consistent revenue growth (17.40% YoY) showing market expansion
Strong analyst consensus with a 'strong_buy' rating and target price of $40.83
Key Risks
Severe overvaluation relative to deterministic benchmarks (Graham/Intrinsic)
Massive insider liquidation ($419.26M sold) by CEO, CFO, and Directors
Very low net profit margin (3.40%) leaving little room for operational error
Bearish technical trend (10/100) suggesting negative price momentum
High Price-to-Book ratio (11.67) indicating the stock is priced far above its tangible assets
AI Fair Value Estimate
Based on comprehensive analysis
$12.5
-67.0% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
45
Moderate
15
85
70
55
0
AI Verdict
Overvalued Growth Play
Key drivers: Insider Selling, Valuation Gap, EPS Growth
Confidence
90%
Value
15/100
Ref P/E 48.63, Graham Number $7.55
Positives
- Forward P/E is lower than trailing P/E
Watchpoints
- Price is ~5x the Graham Number
- P/B ratio of 11.67 is excessive
- Trading significantly above intrinsic value
Future
85/100
Ref 75.2% Q/Q Earnings Growth
Positives
- High Q/Q earnings growth
- Strong revenue trajectory
- Positive analyst targets
Watchpoints
- Growth must be perfect to justify current multiple
Past
70/100
Ref 1Y Change +57.2%
Positives
- Strong 1Y price performance (+57.2%)
- Consistent earnings beats in recent quarters
Watchpoints
- Recent technical trend has turned bearish
Health
55/100
Ref Piotroski F-Score 4/9
Positives
- Very low Debt/Equity (0.21)
- Healthy Current Ratio (1.38)
Watchpoints
- Piotroski F-Score of 4/9 is only mediocre/stable
Dividend
0/100
Ref Dividend Strength 0/100
Positives
No standout positives identified.
Watchpoints
- No dividend payments
- 0% payout ratio
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$37.93
Analyst Target
$40.83
Upside/Downside
+7.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for GRDN and closest competitors.
Updated 2026-04-27
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
GRDN
Guardian Pharmacy Services, Inc.
Primary
|
+137.1% | +137.1% | +57.2% | +30.6% | +11.0% | +1.6% |
|
RARE
Ultragenyx Pharmaceutical Inc.
Peer
|
-76.5% | -39.5% | -30.5% | -24.0% | +21.3% | +6.5% |
|
LFST
LifeStance Health Group, Inc.
Peer
|
-70.8% | -18.8% | -5.5% | +26.7% | -3.6% | +1.4% |
|
APLS
Apellis Pharmaceuticals, Inc.
Peer
|
-59.8% | -70.9% | -22.3% | -23.8% | -15.1% | -5.6% |
|
ZLAB
Zai Lab Limited
Peer
|
-87.4% | -39.1% | -34.9% | -21.9% | +25.2% | -6.9% |
GRD
Guardian Pharmacy Services, Inc.
Primary
5Y
+137.1%
3Y
+137.1%
1Y
+57.2%
6M
+30.6%
1M
+11.0%
1W
+1.6%
RAR
Ultragenyx Pharmaceutical Inc.
Peer
5Y
-76.5%
3Y
-39.5%
1Y
-30.5%
6M
-24.0%
1M
+21.3%
1W
+6.5%
LFS
LifeStance Health Group, Inc.
Peer
5Y
-70.8%
3Y
-18.8%
1Y
-5.5%
6M
+26.7%
1M
-3.6%
1W
+1.4%
APL
Apellis Pharmaceuticals, Inc.
Peer
5Y
-59.8%
3Y
-70.9%
1Y
-22.3%
6M
-23.8%
1M
-15.1%
1W
-5.6%
ZLA
Zai Lab Limited
Peer
5Y
-87.4%
3Y
-39.1%
1Y
-34.9%
6M
-21.9%
1M
+25.2%
1W
-6.9%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
48.63
Forward P/E
28.13
PEG Ratio
N/A
P/B Ratio
11.67
P/S Ratio
1.68
EV/Revenue
1.65
EV/EBITDA
23.32
Market Cap
$2.44B
Profitability
Profit margins and return metrics
Profit Margin
3.4%
Operating Margin
8.89%
Gross Margin
20.21%
ROE
26.61%
ROA
13.68%
Growth
Revenue and earnings growth rates
Revenue Growth
+17.4%
Earnings Growth
N/A
Q/Q Revenue Growth
+17.44%
Q/Q Earnings Growth
+75.2%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.21
Low debt
Current Ratio
1.38
Good
Quick Ratio
1.04
Good
Cash/Share
$1.04
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.4B
Gross Margin
21.5%
Op. Margin
7.7%
Net Margin
5.3%
Total Assets
$0.4B
Liabilities
$0.2B
Equity
$0.2B
Debt/Equity
0.95x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
88%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-06
$N/A
2026-03-11
$0.37
+38.3% surprise
2025-11-10
$0.25
+6.4% surprise
2025-08-11
$0.14
-9.7% surprise
Healthcare Sector Comparison
Comparing GRDN against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
P/E Ratio
48.63
This Stock
vs
75.44
Sector Avg
-35.5%
(Discount)
Return on Equity (ROE)
26.61%
This Stock
vs
-88.14%
Sector Avg
-130.2%
(Below Avg)
Profit Margin
3.4%
This Stock
vs
-16.28%
Sector Avg
-120.9%
(Weaker)
Debt to Equity
0.21
This Stock
vs
2.66
Sector Avg
-92.3%
(Less Debt)
Revenue Growth
17.4%
This Stock
vs
124.04%
Sector Avg
-86.0%
(Slower)
Current Ratio
1.38
This Stock
vs
4.47
Sector Avg
-69.2%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
GRDN
Guardian Pharmacy Services, Inc.
|
BEARISH | $2.44B | 48.63 | 26.6% | 3.4% | $37.93 | |
|
RARE
Ultragenyx Pharmaceutical Inc.
|
BEARISH | $2.44B | - | -608.5% | -85.4% | $24.81 | Compare |
|
LFST
LifeStance Health Group, Inc.
|
NEUTRAL | $2.45B | 320.0 | 0.7% | 0.7% | $6.4 | Compare |
|
APLS
Apellis Pharmaceuticals, Inc.
|
BEARISH | $2.42B | 105.22 | 7.5% | 2.2% | $18.94 | Compare |
|
ZLAB
Zai Lab Limited
|
BEARISH | $2.47B | - | -22.6% | -38.1% | $21.88 | Compare |
GRDN
Guardian...
BEARISH
Mkt Cap
$2.4B
P/E
48.6
ROE
26.6%
Price
$37.93
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-27 | BINDLEY WILLIAM E | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award | 6,100,175 | - |
| 2026-03-27 | BURKE FRED | Chief Executive Officer | Stock Award | 1,298,826 | - |
| 2026-03-27 | ACKERMAN JOHN | Director | Stock Award | 1,884,996 | - |
| 2026-03-27 | MORRIS DAVID K | Chief Financial Officer | Stock Award | 641,869 | - |
| 2026-03-27 | FORBES KENDALL | Officer | Stock Award | 608,570 | - |
| 2026-03-27 | SALENTINE THOMAS J. JR. | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award | 6,100,175 | - |
| 2026-03-27 | BINDLEY CAPITAL PARTNERS I, L.L.C | Beneficial Owner of more than 10% of a Class of Security | Stock Award | 6,100,175 | - |
| 2026-03-27 | PHARMACY INVESTORS, LLC | Beneficial Owner of more than 10% of a Class of Security | Stock Award | 1,413,939 | - |
| 2026-03-27 | CARDINAL EQUITY FUND L P | Beneficial Owner of more than 10% of a Class of Security | Stock Award | 471,057 | - |
| 2026-03-20 | BINDLEY WILLIAM E | Director and Beneficial Owner of more than 10% of a Class of Security | Sale | 3,570,677 | $105,986,620 |
| 2026-03-20 | BURKE FRED | Chief Executive Officer | Sale | 671,432 | $19,929,780 |
| 2026-03-20 | ACKERMAN JOHN | Director | Sale | 1,103,364 | $32,750,602 |
| 2026-03-20 | MORRIS DAVID K | Chief Financial Officer | Sale | 187,855 | $5,576,006 |
| 2026-03-20 | FORBES KENDALL | Officer | Sale | 346,672 | $10,290,092 |
| 2026-03-20 | SALENTINE THOMAS J. JR. | Director and Beneficial Owner of more than 10% of a Class of Security | Sale | 3,570,677 | $105,986,620 |
BINDLEY WILLIAM E
Director and Beneficial Owner of more than 10% of a Class of Security
2026-03-27
6,100,175 shares
BURKE FRED
Chief Executive Officer
2026-03-27
1,298,826 shares
ACKERMAN JOHN
Director
2026-03-27
1,884,996 shares
MORRIS DAVID K
Chief Financial Officer
2026-03-27
641,869 shares
FORBES KENDALL
Officer
2026-03-27
608,570 shares
SALENTINE THOMAS J. JR.
Director and Beneficial Owner of more than 10% of a Class of Security
2026-03-27
6,100,175 shares
BINDLEY CAPITAL PARTNERS I, L.L.C
Beneficial Owner of more than 10% of a Class of Security
2026-03-27
6,100,175 shares
PHARMACY INVESTORS, LLC
Beneficial Owner of more than 10% of a Class of Security
2026-03-27
1,413,939 shares
CARDINAL EQUITY FUND L P
Beneficial Owner of more than 10% of a Class of Security
2026-03-27
471,057 shares
BINDLEY WILLIAM E
Director and Beneficial Owner of more than 10% of a Class of Security
2026-03-20
3,570,677 shares
·
$105,986,620
BURKE FRED
Chief Executive Officer
2026-03-20
671,432 shares
·
$19,929,780
ACKERMAN JOHN
Director
2026-03-20
1,103,364 shares
·
$32,750,602
MORRIS DAVID K
Chief Financial Officer
2026-03-20
187,855 shares
·
$5,576,006
FORBES KENDALL
Officer
2026-03-20
346,672 shares
·
$10,290,092
SALENTINE THOMAS J. JR.
Director and Beneficial Owner of more than 10% of a Class of Security
2026-03-20
3,570,677 shares
·
$105,986,620
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
6 analysts
B of A Securities
2026-04-27
Buy
Truist Securities
2026-04-13
Buy
Buy
Jefferies
2026-03-30
Buy
Oppenheimer
2026-03-12
Outperform
Outperform
Truist Securities
2026-03-12
Buy
Buy
Stephens & Co.
2026-01-14
Overweight
Overweight
Truist Securities
2025-11-14
Buy
Buy
Past News Coverage
Recent headlines mentioning GRDN from our newsroom.
Newest → oldest
No matching news yet.